Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan

Nishino, Ayako; Kawashiri, S.-Y.; Koga, Tomohiro; Iwamoto, Naoki; Ichinose, Kunihiro; Tamai, Mami; Nakamura, Hideki; Origuchi, Tomoki; Ueki, Yukitaka; Yoshitama, Tamami; Eiraku, Nobutaka; Matsuoka, Naoki; Okada, Akitomo; Fujikawa, Keita; Hamada, Hirofumi; Tsuru, Tomomi; Nagano, Shuji; Arinobu, Yojiro; Hidaka, Toshihiko; Kawakami, Atsushi

doi:10.1002/acr.23551

Cited by 26 publications

(28 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRP is widely used as marker of inflammation. However, the CRP level is low in patients using biological preparations even when the disease remains active, and so it may not accurately reflect the disease activity [ 9 , 14 , 15 ]. In the present study, the baseline CRP level was in the normal range in 60.5% of the patients using bDMARDs.…”

Section: Discussionmentioning

confidence: 99%

Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis

Tokai¹,

Kotani²,

Yoshikawa³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to clarify whether serum matrix metalloproteinase 3 (MMP-3) levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA).MethodsForty three patients with RA were treated with iguratimod as add-on therapy to bDMARDs. They were classified into remission and non-remission groups at 24 weeks of iguratimod therapy. Remission was defined as a state with a disease activity score (DAS) <2.6 in 28 joints (termed DAS remission) and total power Doppler ultrasound (US) score <3 (termed US remission). The serum MMP-3 levels at baseline and at 12 weeks were compared between these two groups.ResultsThere were no significant differences in the serum MMP-3 levels at baseline between the DAS and US remission groups and the non-remission group. The serum MMP-3 levels at 12 weeks in the US remission group were significantly lower than those in the non-remission group. The ratios of the serum MMP-3 levels at baseline to those at 12 weeks in both the DAS and US remission groups were significantly lower than those in the non-remission group. An MMP-3 ratio <0.86 was determined as the cut-off value to predict US remission at 24 weeks.ConclusionOur findings suggest that the ratios of the serum MMP-3 levels at baseline to those at 12 weeks could be used to predict remission in RA patients who are administered iguratimod as an add-on to bDMARDs.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis

Tokai¹,

Kotani²,

Yoshikawa³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…We de ned PD remission as a total PD score of 0 at 6 months. Interobserver reliability was con rmed in a previous investigation [27].…”

Section: Musculoskeletal Ultrasound Assessmentmentioning

confidence: 64%

“…This study is part of an ongoing non-randomized multicenter prospective cohort study [KUDOS] of patients with active RA who received bDMARD or tsDMARD therapy at 27 participating rheumatology centers from the Kyushu region of Japan since June 2013 [27][28][29]. We evaluated therapeutic e cacy by determining the patients' clinical disease activity, MSUS score, and serum biomarkers at baseline and at 3, 6, 9, 12, 18, and 24 months starting from the initiation of new bDMARD or tsDMARD.…”

Section: Patientsmentioning

confidence: 99%

“…Compared to clinical and radiographic examinations, MSUS provides a straightforward and more accurate detection of both in ammation and damage at the joint level [25,26]. We have conducted a multicenter prospective observational cohort study of patients with active RA who received bDMARDs or targeted synthetic DMARDs (tsDMARDs) therapy at 27 participating rheumatology centers from the Kyushu region of Japan since June 2013[Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study (KUDOS)] [27][28][29]. We evaluated the therapeutic e cacy of the bDMARDs and tsDMARDs by clinical measurements, MSUS, and biomarker assessments.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association Between Serum Bone Biomarker Levels and Therapeutic Response to Abatacept in Patients With Rheumatoid Arthritis (Ra): a Multicenter Ra Ultrasound Prospective Cohort Study in Japan

Kawashiri

Endo

Nishino

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept.Methods: We enrolled 59 RA patients treated with abatacept from a multicenter prospective ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients' clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. 'Power Doppler (PD) responder' was defined as a patient whose Δtotal PD score over 6 months was greater than the median change.Results: Abatacept significantly improved clinical disease activity as well as the MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the introduction of abatacept (p=0.016). The ΔSOST and ΔOPG values were negatively correlated with the Δtotal PD score (rs= −0.31, p<0.05 and rs= −0.34, p<0.01, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n=30) compared to the non-PD responders (n=29) (p=0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p=0.043) was an independent predictor of PD responder status.Conclusion: Serum levels of bone biomarkers may be useful for predicting RA patients' therapeutic response to abatacept.Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort studyTrial registration number: UMIN000012524Date of registration: 12/9/2013URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657

show abstract

“…Synovitis, tenosynovitis and peritendonitis are key features of active inflammatory arthritis in patients with peripheral rheumatic disorders 1. They can be detected using contrast-enhanced MRI or ultrasonography 2 3. CT is to date not recommended by imaging guidelines for rheumatoid arthritis 4.…”

Section: Introductionmentioning

confidence: 99%

Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis

et al. 2018

View full text Add to dashboard Cite

PurposeTo prove the feasibility and measure the diagnostic accuracy of contrast-enhanced ultra-low-dose CT (ULD-CT) for the depiction of inflammatory soft-tissue changes (synovitis, tenosynovitis and peritendonitis) in patients with arthritis of the hand.Materials and methodsIn this institutional review board–approved study, 36 consecutive patients over the age of 50 with suspected rheumatoid arthritis underwent ULD-CT (estimated radiation exposure <0.01 mSv) and MRI of the hand with weight-adapted intravenous contrast administration. ULD-CT subtraction and MR images were assessed for synovitis, tenosynovitis and peritendonitis by three readers using a modified Rheumatoid Arthritis MRI Score (RAMRIS). Patients were asked which modality they would prefer for future examinations. Sensitivity and specificity of ULD-CT for detection of inflammatory changes were calculated using MRI as standard of reference. The sum scores were correlated using Pearson’s r.ResultsAll 36 patients showed synovitis in MRI. ULD-CT had 69% sensitivity on the patient level and 65% on the joint level with 87% specificity. Sensitivity was higher in patients with more severe inflammation (80% for MRI RAMRIS >1). There was almost perfect correlation between the modified RAMRIS sum scores of ULD-CT and MRI (Pearson’s r=0.94). Regarding preferences for future examinations, 85% preferred ULD-CT over MRI. ULD-CT detected more differential diagnoses than MRI (8 vs 2/12).Conclusion Contrast-enhanced ULD-CT of the hand allows for depiction of soft-tissue inflammation at the hand and can be achieved using very low radiation exposure (<0.01 mSv). ULD-CT may evolve to a fast and comfortable alternative to MRI, although it is not as sensitive as MRI for detecting mild disease.

show abstract

Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan

Abstract: This present prospective US cohort has for the first time shown the variables that are associated with initial PD response to b/tsDMARDs.

Cited by 26 publications

References 30 publications

Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis

Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis

Association Between Serum Bone Biomarker Levels and Therapeutic Response to Abatacept in Patients With Rheumatoid Arthritis (Ra): a Multicenter Ra Ultrasound Prospective Cohort Study in Japan

Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis

Contact Info

Product

Resources

About